OA10.07 Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer Patients: Analysis From AURA17 Trial

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.293
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.03-08 Analysis of ESR1 Mutation Spectrum From Non-Small-Cell Lung Cancer in Chinese Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib

Clinical Cancer Research
Cancer ResearchOncology
2018English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Novel Drug-Resistance Mechanisms of Pemetrexed-Treated Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

P1.03-02 Analysis of SMAD4 Aberrations in Chinese Patients With Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancers
Cancer ResearchOncology
2019English

Clinical Modality of Resistance and Subsequent Management of Patients With Advanced Non-Small Cell Lung Cancer Failing Treatment With Osimertinib

Targeted Oncology
Cancer ResearchOncologyPharmacology
2019English

Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy